Can You Breastfeed While Taking Mounjaro?

Last reviewed: July 15, 2026

Last updated: July 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) is a powerful GLP-1 receptor agonist and GIP receptor agonist used for weight loss and type 2 diabetes, but its safety during breastfeeding remains unclear because clinical trials have not studied how much of the drug passes into breast milk. If you are nursing and considering tirzepatide therapy, understanding the available evidence and exploring personalized alternatives with your doctor is essential to protect your infant while supporting your own health goals.

Does Tirzepatide Pass Into Breast Milk?

Tirzepatide is a large peptide molecule designed to target GLP-1 and GIP receptors in the body. Because of its molecular size and the way peptides are typically broken down in the digestive system, scientists expect that any tirzepatide in breast milk would likely be digested by an infant rather than absorbed intact. However, the FDA and pharmaceutical manufacturers classify tirzepatide as Category C for pregnancy and lactation, meaning human data is insufficient and animal studies have not been completed.

No clinical studies have measured tirzepatide concentration in human breast milk, so absolute safety cannot be guaranteed. The manufacturer of Mounjaro recommends that nursing mothers either discontinue the medication or stop breastfeeding, reflecting the cautious regulatory approach when direct lactation data is absent. This recommendation does not mean tirzepatide is definitely harmful to breastfed infants—it reflects the absence of evidence rather than evidence of harm.

Clinical Evidence on GLP-1 Peptides and Lactation

Other GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda) also carry limited lactation data and similar manufacturer guidance to avoid use during breastfeeding. A 2023 review in the Journal of Maternal-Fetal & Neonatal Medicine noted that injectable peptide drugs are rarely studied in nursing populations because of ethical and regulatory constraints. Retrospective case reports exist of women who continued GLP-1 therapy while breastfeeding without reported adverse infant outcomes, but these anecdotal accounts do not replace formal safety trials.

The American Academy of Pediatrics acknowledges that many medications can be used cautiously during breastfeeding if the benefit-to-risk ratio favors treatment. For weight loss medications specifically, the AAP recommends consultation with a lactation specialist and pediatrician to weigh the mother's health needs against potential infant exposure. Your obstetrician and baby's pediatrician are the best sources for individualized risk assessment based on your specific clinical situation.

Alternatives to Tirzepatide During Breastfeeding

PlexusDx offers multiple personalized GLP-1 weight loss options that may be safer or more compatible with breastfeeding decisions. Compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and can be discussed with your healthcare team as a potential lower-risk alternative, though it also carries lactation warnings. Some nursing mothers and their providers may find that focusing on evidence-based lifestyle modifications—structured nutrition, movement, sleep, and stress management—during the breastfeeding period allows them to delay pharmacotherapy until weaning occurs.

If you wish to continue GLP-1 therapy while nursing, your doctor may recommend switching to bottle feeding to eliminate tirzepatide exposure risk entirely. PlexusDx Precision Peptide Genetic Test (a $99 add-on after your first month of treatment) identifies your genetic predispositions across 14 metabolic pathways and 49 peptides, helping you and your healthcare provider select the most effective medication once breastfeeding is no longer a factor. This personalized approach ensures you resume treatment with a compound matched to your biology.

How to Talk to Your Doctor About GLP-1 and Breastfeeding

Before starting or continuing tirzepatide during breastfeeding, schedule a conversation with both your obstetrician and your baby's pediatrician. Bring a list of your weight loss goals, any underlying metabolic conditions, your breastfeeding timeline, and your willingness to consider bottle feeding if needed. Ask your doctor about the specific data (or lack thereof) for tirzepatide in lactation and whether alternatives like semaglutide, lifestyle-first approaches, or delayed therapy until weaning makes sense for you.

PlexusDx provides telemedicine consultations with clinicians experienced in GLP-1 therapy across diverse patient populations, including nursing mothers seeking evidence-based guidance. Our licensed 503A compounding pharmacies serve all 50 states without insurance requirements, so your treatment options remain flexible and accessible no matter your breastfeeding status. When you are ready to restart or begin tirzepatide therapy after nursing ends, PlexusDx can personalize your dose and compound based on your genetic profile and clinical history.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take Mounjaro while breastfeeding?

Mounjaro's manufacturer recommends against use during breastfeeding because human lactation studies do not exist. While tirzepatide is a large peptide unlikely to be absorbed intact by an infant, the absence of direct safety data means your obstetrician and pediatrician should evaluate the risk-benefit ratio for your specific situation. Many nursing mothers choose to delay GLP-1 therapy until weaning or switch to exclusive bottle feeding if medically appropriate.

Is there clinical evidence that tirzepatide hurts breastfed babies?

No direct evidence of harm exists because formal safety trials in nursing mothers have never been conducted. A few retrospective case reports describe women who used GLP-1 agonists during breastfeeding without reported infant problems, but anecdotal cases do not establish safety. Your pediatrician can help you interpret the theoretical risks (minimal absorption due to peptide size) against your personal health priorities.

What GLP-1 options does PlexusDx offer if I am nursing?

PlexusDx compounded semaglutide injection ($189/mo month-to-month, or from $149/mo on the 6-month plan) and tirzepatide injection ($289/mo month-to-month, or from $249/mo on the 6-month plan) both carry lactation precautions similar to brand-name versions. Your best option may be discussing breastfeeding timeline with your provider and resuming or starting GLP-1 therapy after weaning, when PlexusDx's Precision Peptide Genetic Test ($99 add-on) can identify your ideal personalized medication and dose.

Should I stop breastfeeding to take tirzepatide?

That decision is deeply personal and must involve your obstetrician, pediatrician, and lactation specialist. Weight loss is important for long-term health, but breastfeeding also offers significant infant and maternal benefits. Some families prioritize nursing through the planned weaning timeline and delay GLP-1 therapy accordingly; others choose to bottle feed in order to access weight loss treatment sooner. Neither choice is wrong—only your healthcare team can guide the right one for you.

How does PlexusDx Precision Peptide Genetic Testing help me after I stop breastfeeding?

PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, MC4R, and 145+ other genetic insights to map your metabolic pathways across 14 systems and 49 peptides. Once you finish nursing, this personalized data helps your clinician choose whether semaglutide, tirzepatide, or a dual compound like GLP-Squared is most likely to deliver results for your unique biology, maximizing efficacy and minimizing side effects.

Related Reading

• Hers Mounjaro
• Hims Mounjaro
• Mounjaro For Hypertension
• Mounjaro For Endometriosis

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.